Actionable Mutations in NSCLC

Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).

Clinical Pearls

Thomas J. Lynch, MD, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses actionable mutations in non-small cell lung cancer (NSCLC).

  • An actionable mutation can be found in 40-45% of patients with NSCLC
  • Second- and third-generation EGFR inhibitors could have greater efficacy than some older-generation drugs
  • The range of actionable mutations in NSCLC continues to increase and physicians are now able to find an agent to interact with the specific mutation of the patient